Bliss GVS Pharma Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the Financial Year 2024-2025'.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has filed its annual Business Responsibility and Sustainability Report (BRSR) for FY2024-25 with the BSE and NSE as required by SEBI's listing rules. The company reported a turnover of ₹66,720.46 lakh and a net worth of ₹1,05,863.31 lakh, with 100% of revenue from pharmaceutical products and 92.27% coming from exports across 44 countries. The workforce comprises 966 permanent employees (about 20% women) and 316 contract workers. The report was prepared on a standalone basis without any external assurance, and it disclosed several small regulatory fines — including penalties for non-compliance with the Factories Act, SEBI's listing rules (delays in director appointment compliance), GST, and customs duty. On the sustainability side, 14.23% of capex was spent on environmental improvements such as a 3.5 MW solar plant, rainwater harvesting, and energy-efficient equipment.
This is a routine annual compliance disclosure and is unlikely to move the stock on its own. Investors should note the export-heavy business model and the various small regulatory penalties, but the disclosures do not indicate any material financial or operational concern.